Efficacy of SBR759 in Lowering Serum Phosphate Levels in Chronic Kidney Disease Patients on Hemodialysis

Phase 2 Completed 321 enrolled Novartis Pharmaceuticals

RandomizedParallel-groupOpen-labelTreatment

Summary

This study will evaluate the efficacy of SBR759 compared to sevelamer HCl in lowering serum phosphate levels in Chronic Kidney Disease patients on hemodialysis

Timeline

Start: 2008-07
Primary completion: 2010-08
Completion: —

Publications

Results Chen JB, Chiang SS, Chen HC, Obayashi S, Nagasawa M, Hexham JM, Balfour A, Junge G, Akiba T, Fukagawa M. Efficacy and safety of SBR759, a novel calcium-free, iron(III)-based phosphate binder, in Asian patients undergoing hemodialysis: A 12-week, randomized, open-label, dose-titration study versus sevelamer hydrochloride. Nephrology (Carlton). 2011 Nov;16(8):743-50. doi: 10.1111/j.1440-1797.2011.01509.x.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	SBR759	Other / unclassified	1 g	Oral
Subject	SBR759	Other / unclassified	1.5 g	Oral
Comparator	Sevelamer	Other / unclassified	0.8 g	—
Comparator	Sevelamer	Other / unclassified	1.6 g	—

Indications

No indication recorded.